Powell Daniel J, Parker Linda L, Rosenberg Steven A
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1201, USA.
J Immunother. 2005 Jul-Aug;28(4):403-11. doi: 10.1097/01.cji.0000170363.22585.5a.
The ability to selectively enrich or deplete T lymphocytes of specific phenotype and function holds significant promise for application in adoptive immunotherapy protocols. Although CD4+ T cells can have an impact on CD8+ T-cell effector function, memory, and maintenance, a subset of CD4+ T cells, CD25+ regulatory T cells (Treg), can regulate peripheral self tolerance and possess the ability to suppress antitumor responses. The authors report the ability to selectively deplete CD25+ Treg cells from patient leukapheresis samples using a clinical-grade, large-scale immunomagnetic system. Using leukapheresis samples containing up to 1.3 x 10(10) white blood cells, efficient depletion of Treg cells was measured by flow cytometric analysis of CD25 expression and FOXP3 expression on post-depletion products. Remnant CD25+ cells could not be detected in CD25-depleted products after short-term culture in IL-2 or enriched following secondary immunomagnetic selection for CD25+ cells, confirming that efficient depletion had occurred. In parallel to efficient enrichment of CD25- cells, immunomagnetic selection resulted in the recovery of Treg cells, since CD25+ lymphocytes removed during depletion were primarily composed of CD4+ T cells that expressed high levels of FOXP3 and possessed suppressive activity against autologous TCR-stimulated CD4+ CD25- T cells in vitro. These results show that selective separation of functional CD25+ Treg cells from large-scale samples can be performed in large scale under clinical-grade conditions with sufficient selection, recovery, viability, ability to expand, and function for potential use in adoptive immunotherapy.
选择性富集或去除特定表型和功能的T淋巴细胞的能力在过继性免疫治疗方案中的应用前景广阔。尽管CD4+ T细胞可影响CD8+ T细胞的效应功能、记忆和维持,但CD4+ T细胞的一个亚群,即CD25+调节性T细胞(Treg),可调节外周自身耐受性并具有抑制抗肿瘤反应的能力。作者报告了使用临床级大规模免疫磁选系统从患者白细胞分离样本中选择性去除CD25+ Treg细胞的能力。使用含有多达1.3×10¹⁰个白细胞的白细胞分离样本,通过对去除后产物上CD25表达和FOXP3表达进行流式细胞术分析来测定Treg细胞的有效去除情况。在IL-2中短期培养后,在CD25去除产物中未检测到残留的CD25+细胞,或在对CD25+细胞进行二次免疫磁选后未富集到CD25+细胞,这证实了有效去除已经发生。与高效富集CD25⁻细胞并行的是,免疫磁选导致了Treg细胞的回收,因为在去除过程中去除的CD25+淋巴细胞主要由表达高水平FOXP3并在体外对自体TCR刺激的CD4+ CD25⁻ T细胞具有抑制活性的CD4+ T细胞组成。这些结果表明,在临床级条件下,可以从大规模样本中大规模地选择性分离功能性CD25+ Treg细胞,且具有足够的分选、回收、活力、扩增能力和功能,可用于过继性免疫治疗。